Collaborative efforts by policymakers, industry leaders, academics, philanthropy and community organizations to develop and implement impact-driven solutions. Tackling the challenge of substandard and falsified (SF) medical products requires sustained collaboration across sectors and regions. This moderated session will explore how policymakers, industry leaders, academia, philanthropy, and community organizations can work together to design and implement impact-driven solutions that strengthen medicine quality and patient safety. Panelists will share examples of innovative partnerships, regulatory capacity-building initiatives, and technology-enabled approaches that advance transparency, accountability, and equitable access to quality-assured medicines. The discussion will highlight lessons learned and priorities for expanding collaboration across global health ecosystems.
Collaborative efforts by policymakers, industry leaders, academics, philanthropy and community organizations to develop and implement impact-driven solutions. Tackling the challenge of substandard and falsified (SF) medical products requires sustained collaboration across sectors and regions. This moderated session will explore how policymakers, industry leaders, academia, philanthropy, and community organizations can work together to design and implement impact-driven solutions that strengthen medicine quality and patient safety. Panelists will share examples of innovative partnerships, regulatory capacity-building initiatives, and technology-enabled approaches that advance transparency, accountability, and equitable access to quality-assured medicines. The discussion will highlight lessons learned and priorities for expanding collaboration across global health ecosystems.
BESAFE2025 besafe@jh.eduTechnical Issues?
If you're experiencing playback problems, try adjusting the quality or refreshing the page.
Questions for Speakers?
Use the Q&A tab to submit questions that may be addressed in follow-up sessions.
